The therapeutic efficacy of LentiVIP was tested in a multiple low-dose STZ-induced animal model of type 1 diabetes. LentiVIP delivery into diabetic animals reduced hyperglycemia, improved glucose tolerance, and prevented weight loss.
[Gene Therapy]
0